BioNTech SE - American Depositary Shares (NQ:BNTX)

85.39 -1.47 (-1.69%)

Delayed Quote Updated: 10:05 AM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets

October 26, 2026

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

From Biotech Insider

Via GlobeNewswire

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

October 26, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

October 25, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

October 22, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

October 20, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

October 19, 2026

From BioNTech SE

Via GlobeNewswire

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? ↗

October 18, 2026

It has been a volatile year for the biotech.

Via The Motley Fool

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline ↗

October 17, 2026

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Via The Motley Fool

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

October 13, 2026

From BioNTech SE

Via GlobeNewswire

Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick? ↗

October 13, 2026

Is bigger always better? Not necessarily.

Via The Motley Fool

BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100? ↗

October 08, 2026

BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.

Via The Motley Fool

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗

October 03, 2026

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

Via The Motley Fool

Topics Intellectual Property

Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗

September 28, 2026

Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.

Via The Motley Fool

Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗

September 22, 2026

The company is looking to prove it can achieve significant success outside the coronavirus market.

Via The Motley Fool

BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗

September 22, 2026

Investors buying this biotech stock now will get its pipeline essentially for free.

Via The Motley Fool

BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗

September 18, 2026

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Via The Motley Fool

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

September 15, 2026

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END

Via FinancialNewsMedia

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

September 15, 2026

A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers

From MarketNewsUpdates.com

Via GlobeNewswire

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

September 14, 2026

From BioNTech SE

Via GlobeNewswire

Why Pfizer Stock Was so Healthy in August ↗

September 08, 2026

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.

Via The Motley Fool

Topics Intellectual Property

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗

September 03, 2026

Both have attracted considerable attention from Wall Street recently.

Via The Motley Fool

Is BioNTech Stock a No-Brainer Buy on the Dip? ↗

September 02, 2026

The company is coming back into the spotlight thanks to recent developments.

Via The Motley Fool

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

August 27, 2026

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

August 27, 2026

From BioNTech SE

Via GlobeNewswire

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology

From MarketNewsUpdates.com

Via GlobeNewswire

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

August 20, 2026

From BioNTech SE

Via GlobeNewswire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 19, 2026

Via Chartmill

BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. ↗

August 13, 2026

BioNTech is preparing for its next phase.

Via The Motley Fool

BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

COVID vaccine demand weakens as BioNTech pivots to oncology with promising clinical data.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

73 74 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.